Akums Drugs & Pharmaceuticals Ltd. engages in the manufacturing and marketing of pharmaceutical products and services. It operates segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), and Branded and Generic Formulations. The CDMO segment involves in the formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on contract basis, job work and testing services. The API segment is engaged in manufacturing and sale of KSM, Intermediate and API products. The Branded and Generic Formulations segment is engaged in marketing and distribution of branded and generic pharmaceutical formulations. The firm’s products include tablets, hard gelatin capsules, soft gelatin capsules, powder in sachets, liquid syrups and suspensions, injections, eye/ear drops, ayurveda and herbal preparations, nutraceutical, and cosmetic preparations. The company was founded by Sanjeev Jain and Sandeep Jain on April 19, 2004 and is headquartered in New Delhi, India.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company